Surrozen (SRZN) Long-Term Investments (2021 - 2022)
Surrozen (SRZN) recorded quarterly Long-Term Investments of $11.8 million in Q1 2022, down 45.6% quarter-over-quarter from $21.7 million in Q4 2021, and down 87.2% on a YoY basis from $92.0 million in Q1 2021.
Surrozen (SRZN) Long-Term Investments (2021 - 2022) Analysis & Trends
Surrozen's Long-Term Investments history runs 2 years deep, the most recent figure standing at $11.8 million for Q1 2022.
- In Q1 2022, Long-Term Investments fell 87.2% year-over-year to $11.8 million; the TTM figure through Mar 2022 stood at $11.8 million (down 87.2% YoY), while the FY2021 annual figure was $21.7 million, changed N/A from the prior year.
- Long-Term Investments was $11.8 million for Q1 2022 at Surrozen, down from $21.7 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $92.0 million in Q2 2021 to a low of $11.8 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 11.78 Mn |
| Dec 31, 2021 | 21.66 Mn |
| Sep 30, 2021 | 25.26 Mn |
| Jun 30, 2021 | 92.03 Mn |
| Mar 31, 2021 | 92.03 Mn |